Current partner codePEPTIDESDE
NCT02773355·Not applicable·OBSERVATIONAL

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

Status

Completed

Phase

Not applicable

Enrollment

27

Locations

14

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.

Interventions

Treatment arms and agents.

DRUG

liraglutide 3.0 mg

Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.

Timeline

From registration to results.

  1. First posted

    May 16, 2016

  2. Study start

    May 16, 2016

  3. Primary completion

    Nov 30, 2021

  4. Study completion

    Feb 28, 2022

  5. Results posted

    Not reported

  6. Registry updated

    Apr 13, 2026

Outcomes

What the study measures.

Primary outcomes

Frequency of pancreatitis

Time frame · Year 0-3

Secondary outcomes

Adverse drug reactions (ADR)

Time frame · Year 0-3

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * The decision to initiate the treatment with commercially available Saxenda® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study * Obese patients (BMI equal to or above 30 kg/m\^2) or overweight patients (BMI Equal to or above 27 kg/m\^2) with at least one weight related comorbidity according to Saxenda® label text in Mexico * Age equal or above 18 years at the time of signing informed consent Exclusion Criteria: * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Hypersensitivity to Saxenda® or to any of its excipients * Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) * Diagnosis of type 1 diabetes

Study locations

14 registered sites.

Mexico. Showing up to 24 locations stored in the fast local snapshot.

Especialidades Médicas del Bosque

Guadalajara, Jalisco, Mexico

Investigación Clínica Especializada, S.C.

Guadalajara, Jalisco, Mexico

Centro de Investigacion Clinica Endocrinologica de Jalisco

Guadalajara, Jalisco, Mexico

Unidad Médica Dentistas

Guadalajara, Jalisco, Mexico

Hospital Bite Medica

Mexico City, México, D.F., Mexico

Hospital San Angel Inn

Mexico City, México, D.F., Mexico

Hospital HMG Coyoacan

Mexico City, México, D.F., Mexico

Hospital San Angel Inn_Mexico City

Mexico City, México, D.F., Mexico

Torre Médica Dalinde

Mexico City, México, D.F., Mexico

Zrii de México Ejecutivo Independiente

Monterrey, Nuevo León, Mexico

Hospital CIMA Hermosillo

Hermosillo, Sonora, Mexico

Hospital Angeles de las Lomas

México, State of Mexico, Mexico

Medica Sur

Mexico City, Mexico

Hospital Angeles de Puebla

Puebla City, Mexico

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Liraglutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.